In this line, the cancer-associated mutations in eRF1 can also disrupt its interactions (e.g., UPF1 and eRF3), further impairing translation termination and potentially contributing to tumorigenesis (Pillay et al., 2016). The gene discussed is UPF1; the disease is cancer.